Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Axonyx' investigational treatment for Alzheimer's disease progression, Posiphen, has been shown to be well tolerated at single doses up to and including 80mg in a dose finding phase I trial.
Subscribe to our email newsletter
Blood levels of Posiphen associated with this study were higher than those associated with beneficial effects on beta-amyloid metabolism in animal models. The build-up of beta-amyloid is generally believed to be causative of the dementia of Alzheimer’s disease. No serious adverse events were reported at any dose level.
A major pathological hallmark of AD is the appearance of senile plaques that are primarily composed of forms of beta-amyloid (A beta) derived from beta-APP. Posiphen appears to modify the metabolism of this protein and as such has potential in the treatment of Alzheimer’s disease.
Current treatment of Alzheimer’s disease focuses primarily on acetylcholinesterase inhibition. The company anticipates initiating a Phase I ascending multiple dose study in the near future.